CANY
EBS icon

Caxton Associates (New York)’s Emergent Biosolutions EBS Stock Holding History

Caxton Associates (New York)’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-50,265
Closed -$369K – 462
2023
Q2 		$369K Sell
50,265
-24,668
-33% -$229K 0.05% 313
2023
Q1 		$776K Buy
74,933
+61,908
+475% +$748K 0.12% 194
2022
Q4 		$154K Sell
13,025
-3,907
-23% -$60.5K 0.01% 399
2022
Q3 		$355K Buy
16,932
+213
+1% +$5.93K 0.05% 299
2022
Q2 		$519K Buy
+16,719
New +$571K 0.05% 263
2020
Q4 		– Sell
-2,637
Closed -$272K – 186
2020
Q3 		$272K Sell
2,637
-3,797
-59% -$409K 0.03% 213
2020
Q2 		$509K Buy
+6,434
New +$479K 0.04% 135

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Caxton Associates (New York)'s EBS Position: Q3 2023 in Review

Caxton Associates (New York) sold out of Emergent Biosolutions (EBS) in Q3 2023, closing a stake of 50,265 shares — an estimated $369K sold.

Caxton Associates (New York) first reported a position in EBS in Q2 2020 and held it in 7 quarters. The position peaked at $776K in Q1 2023. 162 funds tracked by Wall St. Rank hold EBS as of Q3 2023.

  • Caxton Associates (New York) reported no remaining Emergent Biosolutions position as of Q3 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 50,265 Emergent Biosolutions shares in Q3 2023, an estimated $369K.
  • Caxton Associates (New York) first reported a position in Emergent Biosolutions in Q2 2020 and held it in 7 quarters.
  • Caxton Associates (New York)'s Emergent Biosolutions position peaked at $776K in Q1 2023.
  • 162 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2023.

Based on Caxton Associates (New York)'s 13F filing for Q3 2023, filed 14 Nov 2023.